AU2006223374B2 - Biomarkers for ovarian cancer and endometrial cancer: hepcidin - Google Patents

Biomarkers for ovarian cancer and endometrial cancer: hepcidin Download PDF

Info

Publication number
AU2006223374B2
AU2006223374B2 AU2006223374A AU2006223374A AU2006223374B2 AU 2006223374 B2 AU2006223374 B2 AU 2006223374B2 AU 2006223374 A AU2006223374 A AU 2006223374A AU 2006223374 A AU2006223374 A AU 2006223374A AU 2006223374 B2 AU2006223374 B2 AU 2006223374B2
Authority
AU
Australia
Prior art keywords
biomarkers
ovarian cancer
hepcidin
biomarker
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006223374A
Other languages
English (en)
Other versions
AU2006223374A1 (en
Inventor
Robert Bast
Daniel W. Chan
Eric Thomas Fung
Vladimir Podust
Jin Song
Zhen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Texas System
Aspira Womens Health Inc
Original Assignee
Johns Hopkins University
University of Texas System
University of Texas at Austin
Aspira Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, University of Texas System, University of Texas at Austin, Aspira Womens Health Inc filed Critical Johns Hopkins University
Publication of AU2006223374A1 publication Critical patent/AU2006223374A1/en
Assigned to THE JOHNS HOPKINS UNIVERSITY, CIPHERGEN BIOSYSTEMS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment THE JOHNS HOPKINS UNIVERSITY Request for Assignment Assignors: BOARD OF REGNETS, THE UNIVERSITY OF TEXAS SYSTEM, CIPHERGEN BIOSYSTEMS, INC., THE JONES HOPKINS UNIVERSITY
Application granted granted Critical
Publication of AU2006223374B2 publication Critical patent/AU2006223374B2/en
Assigned to Aspira Women’s Health Inc., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE JOHNS HOPKINS UNIVERSITY reassignment Aspira Women’s Health Inc. Request to Amend Deed and Register Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, CIPHERGEN BIOSYSTEMS, INC., THE JOHNS HOPKINS UNIVERSITY
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Pest Control & Pesticides (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AU2006223374A 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer: hepcidin Expired AU2006223374B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66209005P 2005-03-11 2005-03-11
US60/662,090 2005-03-11
PCT/US2006/008578 WO2006099126A2 (en) 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer: hepcidin

Publications (2)

Publication Number Publication Date
AU2006223374A1 AU2006223374A1 (en) 2006-09-21
AU2006223374B2 true AU2006223374B2 (en) 2011-07-21

Family

ID=36992262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006223374A Expired AU2006223374B2 (en) 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer: hepcidin

Country Status (11)

Country Link
US (2) US7510842B2 (https=)
EP (1) EP1869462B1 (https=)
JP (1) JP5069214B2 (https=)
KR (1) KR101310000B1 (https=)
CN (1) CN101189516A (https=)
AU (1) AU2006223374B2 (https=)
CA (1) CA2602088C (https=)
IL (1) IL185496A (https=)
MX (1) MX2007011024A (https=)
NZ (1) NZ560976A (https=)
WO (1) WO2006099126A2 (https=)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP2199801B1 (en) * 2004-07-14 2013-05-29 The Regents of The University of California Biomarkers for early detection of ovarian cancer
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP4801930B2 (ja) * 2005-05-02 2011-10-26 株式会社Ｍｃｂｉ 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
US7672916B2 (en) * 2005-08-16 2010-03-02 The Trustees Of Columbia University In The City Of New York Methods, systems, and media for music classification
US7972770B2 (en) * 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530167A1 (en) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Microfluidic Devices
US20090173876A1 (en) * 2006-07-21 2009-07-09 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
WO2008047485A1 (en) * 2006-10-17 2008-04-24 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
WO2008049175A1 (en) * 2006-10-24 2008-05-02 Katholieke Universiteit Leuven High discriminating power biomarker diagnosing
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
EP2210099A4 (en) * 2007-03-27 2011-03-16 Vermillion Inc BIOMARKER FOR OVARIAL CARCINOMA
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US8187827B2 (en) 2007-05-31 2012-05-29 Naohisa Tomosugi Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
CA2694112A1 (en) * 2007-07-20 2009-01-29 The University Of Utah Research Foundation Identification and quantification of biomarkers for evaluating the risk of preterm birth
EP2203743A4 (en) * 2007-09-20 2011-03-02 Univ Louisville Res Found PEPTIDE BIOMARKER FOR PREDICTING WEARNING OF THE KIDNEY FUNCTION AND A CHILDNESS
EP2220506B1 (en) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarkers for the detection of early stage ovarian cancer
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
EP2222345B1 (en) * 2007-11-23 2016-03-23 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
MX2011001445A (es) * 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
EP2328931B1 (en) * 2008-08-06 2013-08-14 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9321818B2 (en) * 2010-02-09 2016-04-26 Academia Sinica Dermcidin-derived peptides for lung cancer diagnostics
EP4484577A3 (en) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US20130236977A1 (en) * 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
US20120046185A1 (en) * 2010-08-06 2012-02-23 Vermillion, Inc. Panel of biomarkers for ovarian cancer
CN102375063A (zh) * 2010-08-23 2012-03-14 湖州赛尔迪生物医药科技有限公司 一种常见蛋白质的免疫质谱试剂盒及制备方法
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
CA2818593A1 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
EP3216872B1 (en) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
MX357292B (es) 2012-07-19 2018-07-04 Toray Industries Método para detectar cáncer.
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
WO2014152006A2 (en) * 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
TWI598577B (zh) * 2014-03-28 2017-09-11 梅托珍尼克斯股份有限公司 Method for obtaining data for determining possibility of carcinogenesis of endometriotic ovarian cysts, and diagnostic apparatus thereof
EP2955517A1 (de) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Stabilisierung von Körperflüssigkeitsproben durch die Zugabe von Detergenz
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB2530521B (en) * 2014-09-24 2020-06-10 Map Ip Holding Ltd Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin
US20170299607A1 (en) * 2014-09-24 2017-10-19 Map Ip Holding Limited Methods For Providing A Prognosis Of Pregnancy
KR20180029046A (ko) 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN106872593B (zh) * 2017-02-04 2021-05-04 江西省妇幼保健院 溶血磷脂酸作为标志物在检测子宫内膜异位症中的应用
EP4530633A3 (en) 2017-08-18 2026-03-25 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN111148844A (zh) 2017-09-01 2020-05-12 韦恩生物科技股份公司 鉴定和使用糖肽作为诊断和治疗监测的生物标记物
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
EP4107525A4 (en) * 2020-02-19 2024-08-14 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
US20230280349A1 (en) * 2022-03-01 2023-09-07 The University Of Chicago Methods of Differentiating a Malignant Tumor from a Non-Malignant Tumor
EP4627348A1 (en) * 2022-12-02 2025-10-08 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
WO2024192014A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Endometrial cancer detection proteins and methods of use thereof
CN119757576A (zh) * 2024-12-26 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于区分健康与宫颈癌的代谢标志物组合及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
AU2003235749A1 (en) * 2002-01-07 2003-07-24 John Hopkins University Biomarkers for detecting ovarian cancer
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
RU2359268C2 (ru) * 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7670792B2 (en) * 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer

Also Published As

Publication number Publication date
EP1869462A2 (en) 2007-12-26
US7510842B2 (en) 2009-03-31
CN101189516A (zh) 2008-05-28
KR20080044801A (ko) 2008-05-21
AU2006223374A1 (en) 2006-09-21
IL185496A0 (en) 2008-01-06
JP5069214B2 (ja) 2012-11-07
IL185496A (en) 2012-07-31
WO2006099126A3 (en) 2006-12-07
CA2602088A1 (en) 2006-09-21
CA2602088C (en) 2021-07-27
MX2007011024A (es) 2009-11-23
US20070054329A1 (en) 2007-03-08
KR101310000B1 (ko) 2013-09-25
WO2006099126A2 (en) 2006-09-21
NZ560976A (en) 2011-06-30
JP2008533471A (ja) 2008-08-21
EP1869462B1 (en) 2013-05-08
US20100068724A1 (en) 2010-03-18
EP1869462A4 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
AU2006223374B2 (en) Biomarkers for ovarian cancer and endometrial cancer: hepcidin
US20220317126A1 (en) Biomarkers for ovarian cancer ctap3-related proteins
US20210181207A1 (en) Biomarkers for Ovarian Cancer: B2 Microglobulin
EP1910821A2 (en) Biomarkers for ovarian cancer
WO2005098447A2 (en) Biomarkers for ovarian cancer
US8221984B2 (en) Biomarkers for ovarian cancer
AU2015210343B2 (en) BIOMARKERS FOR OVARIAN CANCER: ß-2 MICROGLOBULIN
AU2012216473B2 (en) Biomarkers for ovarian cancer: beta-2 microglobulin
US20150153348A1 (en) BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: CIPHERGEN BIOSYSTEMS, INC.; THE JOHNS HOPKINS UNIV

Free format text: FORMER NAME: CIPHERGEN BIOSYSTEMS, INC.; THE JONES HOPKINS UNIVERSITY; BOARD OF REGNETS, THE UNIVERSITY OF TEXAS SYSTEM

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER NAME(S): CIPHERGEN BIOSYSTEMS, INC.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THE JOHNS HOPKINS UNIVERSITY

Owner name: ASPIRA WOMEN'S HEALTH INC.

Free format text: FORMER NAME(S): CIPHERGEN BIOSYSTEMS, INC.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THE JOHNS HOPKINS UNIVERSITY

Owner name: THE JOHNS HOPKINS UNIVERSITY

Free format text: FORMER NAME(S): CIPHERGEN BIOSYSTEMS, INC.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THE JOHNS HOPKINS UNIVERSITY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired